Search Results - "ALINGS, Marco"

Subclinical Atrial Fibrillation in Older Patients by Healey, Jeff S, Alings, Marco, Ha, Andrew, Leong-Sit, Peter, Birnie, David H, de Graaf, Jacob J, Freericks, Michel, Verma, Atul, Wang, Jia, Leong, Darryl, Dokainish, Hisham, Philippon, Francois, Barake, Walid, McIntyre, William F, Simek, Kim, Hill, Michael D, Mehta, Shamir R, Carlson, Mark, Smeele, Frank, Pandey, A Shekhar, Connolly, Stuart J

“…BACKGROUND:Long-term continuous electrocardiographic monitoring shows a substantial prevalence of asymptomatic, subclinical atrial fibrillation (SCAF) in…”
Get full text

Effects of a stepwise, structured LDL-C lowering strategy in patients post-acute coronary syndrome by Omar Khader, Aaram, van Trier, Tinka, van der Brug, Sander, Liem, An-ho, Groenemeijer, Bjorn E., Schut, Astrid, Jorstad, Harald T., Martens, Fabrice M.A.C., Alings, Marco A.M.W.

“…Objective Low-density lipoprotein cholesterol (LDL-C) lowering constitutes a cornerstone of secondary prevention of atherosclerotic cardiovascular disease…”
Get full text

Stroke Outcomes in the COMPASS Trial by Sharma, Mukul, Hart, Robert G, Connolly, Stuart J, Bosch, Jackie, Shestakovska, Olga, Ng, Kelvin K.H, Catanese, Luciana, Keltai, Katalin, Aboyans, Victor, Alings, Marco, Ha, Jong-Won, Varigos, John, Tonkin, Andrew, O’Donnell, Martin, Bhatt, Deepak L, Fox, Keith, Maggioni, Aldo, Berkowitz, Scott D, Bruns, Nancy Cook, Yusuf, Salim, Eikelboom, John W

“…BACKGROUND:Strokes were significantly reduced by the combination of rivaroxaban plus aspirin in comparison with aspirin in the COMPASS trial (Cardiovascular…”
Get full text

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial by Wallentin, Lars, Prof, Yusuf, Salim, Prof, Ezekowitz, Michael D, Prof, Alings, Marco, MD, Flather, Marcus, MD, Franzosi, Maria Grazia, PhD, Pais, Prem, Prof, Dans, Antonio, Prof, Eikelboom, John, MD, Oldgren, Jonas, MD, Pogue, Janice, PhD, Reilly, Paul A, PhD, Yang, Sean, MSc, Connolly, Stuart J, Prof

“…Summary Background Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of…”
Get full text

Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial by Al-Khatib, Sana M, Thomas, Laine, Wallentin, Lars, Lopes, Renato D, Gersh, Bernard, Garcia, David, Ezekowitz, Justin, Alings, Marco, Yang, Hongqui, Alexander, John H, Flaker, Gregory, Hanna, Michael, Granger, Christopher B

“…It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF). A total of 18 201 patients with AF [2786 (15.3%)…”
Get full text

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial by Easton, J Donald, Dr, Lopes, Renato D, MD, Bahit, M Cecilia, MD, Wojdyla, Daniel M, MS, Granger, Christopher B, MD, Wallentin, Lars, MD, Alings, Marco, MD, Goto, Shinya, MD, Lewis, Basil S, MD, Rosenqvist, Mårten, MD, Hanna, Michael, MD, Mohan, Puneet, MD, Alexander, John H, MD, Diener, Hans-Christoph, MD

“…Summary Background In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial…”
Get full text

The Effect of Rate Control on Quality of Life in Patients With Permanent Atrial Fibrillation: Data From the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) Study by GROENVELD, Hessel F, CRIJNS, Harry J. G. M, VAN GELDER, Isabelle C, VAN DEN BERG, Maarten P, VAN SONDEREN, Eric, MARCO ALINGS, A, TIJSSEN, Jan G. P, HILLEGE, Hans L, TUININGA, Ype S, VAN VELDHUISEN, Dirk J, RANCHOR, Adelita V

“…The aim of this study was to investigate the influence of rate control on quality of life (QOL). The RACE II (Rate Control Efficacy in Permanent Atrial…”
Get full text

Efficacy and safety of low‐dose digoxin in patients with heart failure. Rationale and design of the DECISION trial by Veldhuisen, Dirk J., Rienstra, Michiel, Mosterd, Arend, Alings, A. Marco, Asselt, Antoinette D.J., Bouvy, Marcel L, Tijssen, Jan G.P., Schaap, Jeroen, Wall, Ernst E., Voors, Adriaan A., Boorsma, Eva M., Lok, Dirk J.A., Crijns, Harry J.G.M., Schut, Astrid, Vijver, Marlene A.T., Voordes, Geert H.D., Vos, Agaath H., Maas‐Soer, Ester L., Smit, Nicoline W., Touw, Daan J., Samuel, Michelle, Meer, Peter, Veldhuisen, Dirk J., Meer, Peter, Rienstra, Michiel, Mosterd, Arend, Alings, Marco, Tijssen, Jan, Asselt, Thea, Bouvy, Marcel, Wall, Ernst E., Schaap, Jeroen, Voors, Adriaan A., Crijns, Harry J. G. M., Gaillard, Carlo, Veeger, Nick

“…Aims Digoxin is the oldest drug in cardiovascular (CV) medicine, and one trial conducted >25 years ago showed a reduction in heart failure (HF)…”
Get full text

Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke by Whitlock, Richard P., Belley-Cote, Emilie P., Paparella, Domenico, Healey, Jeff S., Brady, Katheryn, Sharma, Mukul, Reents, Wilko, Budera, Petr, Baddour, Andony J., Fila, Petr, Devereaux, P.J., Bogachev-Prokophiev, Alexander, Boening, Andreas, Teoh, Kevin H.T., Tagarakis, Georgios I., Slaughter, Mark S., Royse, Alistair G., McGuinness, Shay, Alings, Marco, Punjabi, Prakash P., Mazer, C. David, Folkeringa, Richard J., Colli, Andrea, Avezum, Álvaro, Nakamya, Juliet, Balasubramanian, Kumar, Vincent, Jessica, Voisine, Pierre, Lamy, Andre, Yusuf, Salim, Connolly, Stuart J.

Get full text

Risk of Ventricular Arrhythmia After Implantable Defibrillator Treatment in Anxious Type D Patients by van den Broek, Krista C., PhD, Nyklíček, Ivan, PhD, van der Voort, Pepijn H., MD, Alings, Marco, MD, PhD, Meijer, Albert, MD, PhD, Denollet, Johan, PhD

“…Objectives We sought to examine the combination of adverse psychological factors (anxiety, depression, and distressed or Type D personality) as a predictor of…”
Get full text

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial by Pol, Tymon, Held, Claes, Westerbergh, Johan, Lindbäck, Johan, Alexander, John H., Alings, Marco, Erol, Cetin, Goto, Shinya, Halvorsen, Sigrun, Huber, Kurt, Hanna, Michael, Lopes, Renato D., Ruzyllo, Witold, Granger, Christopher B., Hijazi, Ziad

“…Background Dyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not…”
Get full text

Rate Control Efficacy in Permanent Atrial Fibrillation: Successful and Failed Strict Rate Control Against a Background of Lenient Rate Control by Groenveld, Hessel F., MD, Tijssen, Jan G.P., PhD, Crijns, Harry J.G.M., MD, Van den Berg, Maarten P., MD, Hillege, Hans L., MD, Alings, Marco, MD, Van Veldhuisen, Dirk J., MD, Van Gelder, Isabelle C., MD

“…Objectives This study sought to investigate differences in outcome between patients treated with successful strict, failed strict, and lenient rate control…”
Get full text

Familial Evaluation in Catecholaminergic Polymorphic Ventricular Tachycardia: Disease Penetrance and Expression in Cardiac Ryanodine Receptor Mutation–Carrying Relatives by van der Werf, Christian, Nederend, Ineke, Hofman, Nynke, van Geloven, Nan, Ebink, Corné, Frohn-Mulder, Ingrid M.E, Alings, A. Marco W, Bosker, Hans A, Bracke, Frank A, van den Heuvel, Freek, Waalewijn, Reinier A, Bikker, Hennie, van Tintelen, J Peter, Bhuiyan, Zahurul A, van den Berg, Maarten P, Wilde, Arthur A.M

“…BACKGROUND—Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome associated with mutations in the cardiac ryanodine…”
Get full text

Familial sudden death is an important risk factor for primary ventricular fibrillation : A case-control study in acute myocardial infarction patients by DEKKER, Lukas R. C, BEZZINA, Connie R, VERKERK, Agnes, VERHEUGT, Freek W. A, ZIJLSTRA, Felix, WILDE, Arthur A. M, HENRIQUES, José P. S, TANCK, Michael W, KOCH, Karel T, ALINGS, Marco W, ARNOLD, Alfred E. R, DE BOER, Menko-Jan, GORGELS, Anton P. M, ROLF MICHELS, H

“…Primary ventricular fibrillation (VF) accounts for the majority of deaths during the acute phase of myocardial infarction. Identification of patients at risk…”
Get full text

Digoxin in patients with permanent atrial fibrillation: Data from the RACE II study by Mulder, Bart A., MD, Van Veldhuisen, Dirk J., MD, PhD, Crijns, Harry J.G.M., MD, PhD, Tijssen, Jan G.P., PhD, Hillege, Hans L., MD, PhD, Alings, Marco, MD, PhD, Rienstra, Michiel, MD, PhD, Van den Berg, Maarten P., MD, PhD, Van Gelder, Isabelle C., MD, PhD

“…Background The Atrial Fibrillation Follow-up Investigation of Rhythm Management trial showed that digoxin was associated with increased mortality in patients…”
Get full text

Prevention of Arrhythmia Device Infection Trial by Krahn, Andrew D., Longtin, Yves, Philippon, François, Birnie, David H., Manlucu, Jaimie, Angaran, Paul, Rinne, Claus, Coutu, Benoit, Low, R. Aaron, Essebag, Vidal, Morillo, Carlos, Redfearn, Damian, Toal, Satish, Becker, Giuliano, Degrâce, Michel, Thibault, Bernard, Crystal, Eugene, Tung, Stanley, LeMaitre, John, Sultan, Omar, Bennett, Matthew, Bashir, Jamil, Ayala-Paredes, Felix, Gervais, Philippe, Rioux, Leon, Hemels, Martin E.W., Bouwels, Leon H.R., van Vlies, Bob, Wang, Jia, Exner, Derek V., Dorian, Paul, Parkash, Ratika, Alings, Marco, Connolly, Stuart J.

“…Infection of implanted medical devices has catastrophic consequences. For cardiac rhythm devices, pre-procedural cefazolin is standard prophylaxis but does not…”
Get full text

Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial by Dudink, Elton, Essers, Brigitte, Holvoet, Wouter, Weijs, Bob, Luermans, Justin, Ramanna, Hemanth, Liem, Anho, van Opstal, Jurren, Dekker, Lukas, van Dijk, Vincent, Lenderink, Timo, Kamp, Otto, Kulker, Lennert, Rienstra, Michiel, Kietselaer, Bas, Alings, Marco, Widdershoven, Jos, Meeder, Joan, Prins, Martin, van Gelder, Isabelle, Crijns, Harry

“…Current standard of care for patients with recent-onset atrial fibrillation (AF) in the emergency department aims at urgent restoration of sinus rhythm,…”
Get full text

Randomized Cluster Crossover Trials for Reliable, Efficient, Comparative Effectiveness Testing: Design of the Prevention of Arrhythmia Device Infection Trial (PADIT) by Connolly, Stuart J., MD, Philippon, Francois, MD, Longtin, Yves, MD, Casanova, Amparo, PhD, Birnie, David H., MD, Exner, Derek V., MD, Dorian, Paul, MD, Prakash, Ratika, MD, Alings, Marco, MD, Krahn, Andrew D., MD

“…Abstract Randomized clinical trials are a major advance in clinical research methodology. However, there are myriad important questions about the effectiveness…”
Get full text

Effect of Lenient Versus Strict Rate Control on Cardiac Remodeling in Patients With Atrial Fibrillation by Smit, Marcelle D., MD, Crijns, Harry J.G.M., MD, Tijssen, Jan G.P., PhD, Hillege, Hans L., MD, Alings, Marco, MD, Tuininga, Ype S., MD, Groenveld, Hessel F., MD, Van den Berg, Maarten P., MD, Van Veldhuisen, Dirk J., MD, Van Gelder, Isabelle C., MD

“…Objectives The aim of this study was to evaluate echocardiographic remodeling in permanent atrial fibrillation (AF) patients treated with either lenient or…”
Get full text

INTERBLEED: Design of an International Study of Risk Factors for Gastrointestinal Bleeding and Cardiovascular Events After Gastrointestinal Bleeding by Bosch, Jacqueline, Moayyedi, Paul, Alings, Marco, Avezum, Alvaro, Bangdiwala, Shrikant I., Barkun, Alan, Cassella, Federico, Marchi da Rocha, Aloisio, Duzen, Irfan, Enns, Robert, Forbes, Nauzer, Hamilton, Leah, Islam, Shofiqul, Kilickap, Mustafa, Kruger, Paul, Liang, Yan, Nicolau, Jose C., Nunes, Rafael, O’Donnell, Martin, Oliveira, Gustavo, Rey, Alejandro, Sun, Yihong, Vanassche, Thomas, Verhamme, Peter, Walsh, Michael, Wang, Zhenyu, Wu, Cynthia, Zhao, Li, Zhu, Jun, Eikelboom, John W.

“…Bleeding is the most common adverse event in those with cardiovascular (CV) disease receiving antithrombotic therapy, and it most commonly occurs in the…”
Get full text